A PeptidePrices review of 13 publicly posted FDA warning letters found that storefront closures were the exception after enforcement. Ten warned businesses still sell peptides through public or account-gated storefronts.
In the FDA warning-letter archive, the earliest research-peptide storefront letters PeptidePrices could identify were sent on February 7, 2024. The recipients were US Chem Labs and Helix Chemical Supply.
FDA said both websites sold semaglutide and tirzepatide while publishing material that showed an intended use as human drugs. The sites used research-only language, but FDA's position was that the surrounding claims, dose information, and product presentation mattered more than the disclaimer.
Two and a half years later, US Chem Labs still has an active peptide storefront. Helix is the only seller in this census for which PeptidePrices found neither an operating cited domain nor an apparent successor.
That split previews what happened across the broader enforcement campaign.
PeptidePrices identified 13 publicly posted FDA warning letters sent to online research-peptide sellers from February 2024 through June 2026. As of August 23, ten of those businesses still displayed peptide products or maintained account-gated peptide catalogs. One warned site remained online for supplies and miscellaneous payments but did not expose a public peptide catalog. One displayed a maintenance notice. One appeared inactive.
The warning letters are changing how this market looks. They have usually not removed the seller.
The December 2024 batch
On December 10, 2024, FDA sent four warning letters in one day:
Three of the four original storefronts are still active. Prime Peptides and Swisschems retain public catalogs. Xcel now places its peptide catalog behind an account gate.
Summit's original domain is parked, but the business may not have disappeared.
SummitPep.com was registered on April 7, 2026. The site calls itself Summit Research and has a working catalog, customer accounts, and checkout. It lists “RTA” and “TRZ,” while the site's product data retains retatrutide and tirzepatide as legacy page names. It also advertises legacy RTA pricing to “Founder VIP” customers described as early supporters of Summit Research.
The strongest continuity signal is in the new site's terms, which refer to “Summit Research Peptides,” the exact name on FDA's 2024 letter. Public domain-registration records do not identify the current operator, so PeptidePrices cannot independently confirm common ownership. The newer site nevertheless presents itself as the continuation of the warned business.
That makes the December group a useful snapshot: three original storefronts remain active, and the fourth appears to have resurfaced under a new domain and a more coded catalog.
The 13-letter timeline
After the 2024 letters, FDA warned USApeptide.com in February 2025. Five more letters followed on March 31, 2026, to Gram Peptides, Mile High Compounds, PekCura Labs, Prime Sciences, and Pink Pony Peptides. Wholesale Peptide received the most recent letter in this census on June 17, 2026.
PeptidePrices checked the cited domains, apparent successor sites, and storefronts on August 23.
Each FDA letter concerns specific products and website content. The recurring legal argument is simple: a “research use only” label does not control a product's status when the rest of the site shows an intended use as a human drug.
FDA cited weight-loss and therapeutic claims, dose schedules, descriptions of physiological effects, and instructions that connected products to human use. Each recipient was given 15 working days to respond. A warning letter is FDA's position and an opportunity to correct cited issues, not a court judgment.
FDA's public directory currently shows no closeout letter for any of these 13 sellers. That does not mean no private response occurred. FDA explains that it publishes a closeout letter after evaluating and verifying corrective action.
What changed after the letters
Some warned sellers still use recognizable compound names. Others have made their storefronts less legible to anyone who is not already a customer.
Mile High uses MHC-3 RT and MHC-2 TRZ. Pink Pony uses PinkPony-3 RT and PinkPony-2TZ. Summit uses RTA and TRZ. PekCura often puts a CAS number in the most prominent position. Xcel, Mile High, and Prime Sciences make visitors log in before reaching the complete catalog.
This naming shift extends beyond GLP compounds. PeptidePrices increasingly sees SS-31 listings presented as Elamipretide, MTP-31, MitoShield-31, MS-31, PUR-31, or similar names. Some are recognizable synonyms or vendor-created labels. A buyer should not assume that two listings are chemically identical just because their names look related.
Account gates and coded names make a storefront harder to index and compare. They are not proof of quality, wrongdoing, or chemical identity. For buyers, the practical issue is continuity: when a company changes its domain or renames its catalog, it becomes easier to land on an imitator, misunderstand a product code, or rely on an old certificate that does not match the current lot.
Peptide Sciences shows the scale of one major exit
The largest research-peptide closure of 2026 did not involve a publicly posted warning letter.
Peptide Sciences replaced its storefront with a notice saying it had voluntarily shut down and discontinued research-product sales. The company gave no public reason and warned that websites claiming to be successors or to sell its products were unauthorized.
An outside e-commerce analytics firm, Grips Intelligence, estimates that Peptide Sciences generated $81.3 million in online gross merchandise value in 2025, up more than 50% from the prior year. That is a modeled third-party estimate, not a company revenue disclosure, but it helps explain why the closure mattered to buyers and competitors.
Lilly offered its own interpretation in an August 2026 federal complaint against Lone Star Peptide, describing Peptide Sciences as a seller that shut down because of FDA enforcement pressure. The complaint did not identify a warning letter, injunction, or other public FDA action directed at the company.
What is documented is the aftermath. Competitors quickly marketed themselves as alternatives. Lilly's complaint says Lone Star published a “Peptide Sciences Alternative” page and targeted former customers. One large storefront disappeared, but the buyers and demand around it did not disappear with the domain.
Enforcement is moving beyond warning letters
On August 12, Lilly announced six federal lawsuits involving products represented as retatrutide. Four defendants operated research-use storefronts: Astra Peptides, Legendary Peptides, Lone Star Peptide, and Texas Peptides Inc. The other cases targeted a compounding pharmacy and a medical-spa business.
Lilly's complaints say FDA had issued at least 16 retatrutide-related warning letters. That is a broader count than this article's 13-storefront census. FDA's retatrutide results also include telehealth businesses, a compounding operation, and an active-pharmaceutical-ingredient manufacturer. The census here is limited to online sellers using research, laboratory, or similar storefront framing, whether or not retatrutide appeared in the particular letter.
Lilly is also calling on payment processors, online platforms, shipping companies, and other service providers to stop supporting these sellers. That strategy recognizes something visible in FDA's own record: changing the public claims on a site is different from removing its customer relationships, payment access, or ability to reopen elsewhere.
The takeaway
FDA's warning-letter campaign is real, and its effects are visible. Sellers have removed claims, shortened product names, added login gates, moved domains, and in a few cases stopped public sales.
But the record does not show a market disappearing. Ten of the 13 warned research-peptide businesses still have visible or gated peptide sales. In the December 2024 group, three original storefronts remain active and the fourth has an apparent continuation.
The most important change is that the market is becoming harder to observe. Renamed compounds and private catalogs can preserve sales while removing information that once made storefronts easy to identify, compare, and track over time.
Current status of the 13 warned storefronts
The table records the status observed by PeptidePrices on August 23, 2026.
| FDA recipient | Current status | What a visitor can see now |
|---|---|---|
| US Chem Labs | Active | A public peptide catalog with named products, prices, and add-to-cart controls. |
| Helix Chemical Supply | Inactive | The cited domain did not respond, the related .co domain is parked, and no operating successor was found. |
| Prime Peptides | Active | A public storefront listing retatrutide by name, along with calculators and reconstitution material. |
| Summit Research Peptides | Apparent continuation | SummitPep.com sells coded RTA and TRZ products and uses the warned business's full name in its terms. |
| Swisschems | Active | A public storefront with peptide products, prices, and add-to-cart controls. |
| Xcel Research | Active behind login | Visitors must register or sign in to view the full peptide catalog and shop. |
| USApeptide.com | Commerce site active | The public site sells supplies and accepts miscellaneous payments, while directing visitors to email for a new website. No public peptide catalog was visible. |
| Gram Peptides | Maintenance | The site says it will be back soon. |
| Mile High Compounds | Active behind login | An account gate precedes the peptide catalog, which uses product codes such as MHC-3 RT and MHC-2 TRZ. |
| PekCura Labs | Active | A public peptide catalog that often emphasizes CAS numbers instead of familiar drug names. |
| Prime Sciences | Active behind login | The site advertises in-stock research peptides but requires an account to continue shopping. |
| Pink Pony Peptides | Active | A public catalog using names such as PinkPony-3 RT and PinkPony-2TZ. |
| Wholesale Peptide | Active | A public catalog with product names, prices, quantity controls, and shipping claims. |
Download the census and cite this research
The row-level evidence behind this article is available as a public PeptidePrices dataset:
- Open the dataset landing page
- Download the 13-row CSV
- Download the machine-readable JSON
- Read the complete methodology and data dictionary
Suggested citation: PeptidePrices Research Team. (2026). FDA Research-Peptide Warning-Letter Storefront Census (Version 1.0) [Data set]. PeptidePrices. https://peptideprices.net/research-data/fda-peptide-warning-letters-2026
The dataset is licensed under Creative Commons Attribution 4.0. Version 1.0 preserves the storefront status observed on August 23, 2026 so later updates can be compared against a fixed snapshot.
Methodology and disclosure
PeptidePrices searched FDA's public warning-letter directory and reviewed the complete text of potentially relevant letters. The census includes online sellers offering peptide products under research-use, laboratory-use, or similar framing. It excludes telehealth providers, compounding pharmacies, conventional illegal online pharmacies, API manufacturers, and sellers warned only for non-peptide products such as SARMs.
Current status was checked on August 23, 2026, using the domain cited by FDA and apparent successor domains identified through branding, site terms, product records, and public domain-registration data.
PeptidePrices compares research suppliers and participates in affiliate programs with some sellers in its broader directory. It may earn commissions from eligible referrals. Affiliate status did not determine which warning letters or storefronts were included in this review.